Abiraterone and Enzalutamide for mCRPC

Charles Ryan, MD, Associate Clinical Professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the utility of abiraterone and enzalutamide for patients with metastatic castration-resistant prostate cancer.

Clinical Pearls

• The phase III PREVAIL study looked at enzalutamide versus placebo in chemotherapy-naïve, asymptomatic patients with metastatic castration-resistant prostate cancer
• There was a statistically significant survival benefit and positive prolongation of radiographic progression-free survival in favor of enzalutamide
• Dr. Ryan believes these data will drive the eventual use of this therapy in the chemotherapy-naïve population
• Physician prescribing preferences will ultimately determine how abiraterone and enzalutamide are used

<<< Back to the GU 2014 conference page